Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Champlin

Showing results (71-80 of 217) with videos related to

Pageof 22
Sort By:
BMJ Supportive & Palliative Care|September 2, 2017
Risk factors for falls in older patients with cancerXiaotao Zhang, Ming Sun, Suyu Liu, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 8, 2021
Refractory and Resistant Cytomegalovirus After Hematopoietic Cell Transplant in the Letermovir Primary Prophylaxis EraJoseph Sassine, Fareed Khawaja, Terri Lynn Shigle, et al.
Blood Advances|April 12, 2024
Long-term outcomes after haploidentical stem cell transplantation for hematologic malignanciesSupawee Saengboon, Stefan Ciurea, Uday Popat, et al.
Leukemia & Lymphoma|January 4, 2018
Amifostine reduces gastro-intestinal toxicity after autologous transplantation for multiple myelomaEhsan Malek, Vinita Gupta, Richard Creger, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 11, 2002
Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortalityAshwin Kashyap, John Wingard, Pablo Cagnoni, et al.
Blood|January 17, 2012
The characteristics and outcomes of parainfluenza virus infections in 200 patients with leukemia or recipients of hematopoietic stem cell transplantationRoy F Chemaly, Santosh S Hanmod, Dhanesh B Rathod, et al.
Blood|December 16, 2010
Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutationsElias Jabbour, Jorge Cortes, Fabio P S Santos, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 24, 2007
Results of a retrospective single institution analysis of targeted skeletal radiotherapy with (166)Holmium-DOTMP as conditioning regimen for autologous stem cell transplant for patients with multiple myeloma. Impact on transplant outcomesAnna V Christoforidou, Rima M Saliba, Patricia Williams, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 15, 2014
Central nervous system relapse in adults with acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantationAmir Hamdi, Raya Mawad, Roland Bassett, et al.
Blood|April 20, 2004
Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantationMarcos de Lima, Athanasios Anagnostopoulos, Mark Munsell, et al.
Pageof 22

Showing results (71-80 of 217) with videos related to

Sort By:
Pageof 22
BMJ Supportive & Palliative Care|September 2, 2017
Risk factors for falls in older patients with cancerXiaotao Zhang, Ming Sun, Suyu Liu, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 8, 2021
Refractory and Resistant Cytomegalovirus After Hematopoietic Cell Transplant in the Letermovir Primary Prophylaxis EraJoseph Sassine, Fareed Khawaja, Terri Lynn Shigle, et al.
Blood Advances|April 12, 2024
Long-term outcomes after haploidentical stem cell transplantation for hematologic malignanciesSupawee Saengboon, Stefan Ciurea, Uday Popat, et al.
Leukemia & Lymphoma|January 4, 2018
Amifostine reduces gastro-intestinal toxicity after autologous transplantation for multiple myelomaEhsan Malek, Vinita Gupta, Richard Creger, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 11, 2002
Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortalityAshwin Kashyap, John Wingard, Pablo Cagnoni, et al.
Blood|January 17, 2012
The characteristics and outcomes of parainfluenza virus infections in 200 patients with leukemia or recipients of hematopoietic stem cell transplantationRoy F Chemaly, Santosh S Hanmod, Dhanesh B Rathod, et al.
Blood|December 16, 2010
Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutationsElias Jabbour, Jorge Cortes, Fabio P S Santos, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 24, 2007
Results of a retrospective single institution analysis of targeted skeletal radiotherapy with (166)Holmium-DOTMP as conditioning regimen for autologous stem cell transplant for patients with multiple myeloma. Impact on transplant outcomesAnna V Christoforidou, Rima M Saliba, Patricia Williams, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 15, 2014
Central nervous system relapse in adults with acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantationAmir Hamdi, Raya Mawad, Roland Bassett, et al.
Blood|April 20, 2004
Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantationMarcos de Lima, Athanasios Anagnostopoulos, Mark Munsell, et al.
Pageof 22